HRP20211081T1 - Anti-pro/latentna miostatinska protutijela i njihove uporabe - Google Patents
Anti-pro/latentna miostatinska protutijela i njihove uporabe Download PDFInfo
- Publication number
- HRP20211081T1 HRP20211081T1 HRP20211081TT HRP20211081T HRP20211081T1 HR P20211081 T1 HRP20211081 T1 HR P20211081T1 HR P20211081T T HRP20211081T T HR P20211081TT HR P20211081 T HRP20211081 T HR P20211081T HR P20211081 T1 HRP20211081 T1 HR P20211081T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- isolated
- seq
- pro
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
Claims (15)
1. Izolirano protutijelo, naznačeno time, da posjeduje varijabilnu regiju teškog lanca koja sadrži aminokiselinski slijed od SEQ ID NO: 25 i varijabilnu regiju lakog lanca koja sadrži aminokiselinski slijed od SEQ ID NO: 31, pri čemu se protutijelo specifično veže na pro/latentni miostatin.
2. Izolirano protutijelo prema patentnom zahtjevu 1, naznačeno time, da protutijelo posjeduje teški lanac koji sadrži aminokiselinski slijed od SEQ ID NO: 50 i/ili laki lanac koji sadrži aminokiselinski slijed od SEQ ID NO: 51.
3. Izolirano protutijelo prema patentnom zahtjevu 1 ili zahtjevu 2, naznačeno time, da protutijelo jest ljudsko protutijelo.
4. Izolirano protutijelo prema bilo kojem od patentnih zahtjeva 1 do 3, naznačeno time, da protutijelo sadrži konstatnu domenu IgG4.
5. Izolirano protutijelo prema bilo kojem od patentnih zahtjeva 1 do 4, naznačeno time, da protutijelo sadrži konstatnu domenu IgG4 koja posjeduje supstituciju glavne okosnice od Ser do Pro, koja proizvodi zglob nalik na IgG1 i dopušta formiranje međulančanih disulfidnih veza.
6. Izolirano protutijelo prema bilo kojem od patentnih zahtjeva 1 do 5, naznačeno time, da protutijelo inhibira proteolitičke formacije zrelog miostatina putem toloidne proteaze.
7. Izolirano protutijelo prema patentnom zahtjevu 6, naznačeno time, da protutijelo inhibira proteolitičke formacije zrelog miostatina putem toloidne proteaze s IC50 koji je manji od 1 μM, i/ili križno reagira s ljudskim i mišjim pro/latentnim miostatinom.
8. Postupak in vitro za redukciju aktiviranja miostatinskog receptora u stanici koja se nalazi u mediju koji sadrži pro/latentni miostatin, naznačen time, da postupak obuhvaća dostavljanje u medij protutijela prema bilo kojem od patentnih zahtjeva 1 do 7, u količini koja je učinkovita za inhibiranje proteolitičkog aktiviranja pro/latentnog miostatina.
9. Protutijelo prema bilo kojem od patentnih zahtjeva 1 do 7, naznačeno time, da je za uporabu u postupku liječenja pojedinca koji ima miopatiju, pri čemu navedeni postupak obuhvaća davanje pojedincu učinkovite količine spomenutog protutijela.
10. Farmaceutski pripravak, naznačen time, da sadrži protutijelo prema bilo kojem od patentnih zahtjeva 1 do 7, i farmaceutski prihvatljiv nosač.
11. Farmaceutski pripravak prema patentnom zahtjevu 10, naznačen time, da pripravak je: (i) liofilizirani pripravak, (ii) tekući pripravak, ili (iii) smrznut.
12. Farmaceutski pripravak prema patentnom zahtjevu 11(iii), naznačen time, da je pripravak smrznut na temperaturi koja iznosi -65°C ili manje.
13. Štrcaljka, naznačena time, da sadrži farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 10 do 12.
14. Izolirana nukleinska kiselina, naznačena time, da kodira protutijelo koje posjeduje varijabilnu regiju teškog lanca sa slijedom nukleinske kiseline od SEQ ID NO: 39 i varijabilnu regiju lakog lanca sa slijedom nukleinske kiseline od SEQ ID NO: 45.
15. Izolirana stanica, naznačena time, da sadrži izoliranu nukleinsku kiselinu prema patentnom zahtjevu 14.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562219094P | 2015-09-15 | 2015-09-15 | |
| PCT/US2016/052014 WO2017049011A1 (en) | 2015-09-15 | 2016-09-15 | Anti-pro/latent-myostatin antibodies and uses thereof |
| EP16774748.4A EP3350220B1 (en) | 2015-09-15 | 2016-09-15 | Anti-pro/latent-myostatin antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211081T1 true HRP20211081T1 (hr) | 2021-10-15 |
Family
ID=57043000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211081TT HRP20211081T1 (hr) | 2015-09-15 | 2016-09-15 | Anti-pro/latentna miostatinska protutijela i njihove uporabe |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10751413B2 (hr) |
| EP (3) | EP3350220B1 (hr) |
| JP (3) | JP7107836B2 (hr) |
| KR (3) | KR20250033313A (hr) |
| CN (4) | CN113912718B (hr) |
| AU (2) | AU2016323447B2 (hr) |
| BR (1) | BR112018004981A2 (hr) |
| CA (1) | CA3036652A1 (hr) |
| CO (1) | CO2018002703A2 (hr) |
| CY (1) | CY1124619T1 (hr) |
| DK (2) | DK3350220T3 (hr) |
| EA (1) | EA038146B1 (hr) |
| ES (2) | ES3030258T3 (hr) |
| FI (1) | FI3922645T3 (hr) |
| HR (1) | HRP20211081T1 (hr) |
| HU (1) | HUE055331T2 (hr) |
| IL (2) | IL258121B2 (hr) |
| LT (2) | LT3922645T (hr) |
| MX (5) | MX2018003196A (hr) |
| PL (1) | PL3350220T3 (hr) |
| PT (2) | PT3922645T (hr) |
| RS (1) | RS62330B1 (hr) |
| SI (1) | SI3350220T1 (hr) |
| SM (1) | SMT202100432T1 (hr) |
| WO (1) | WO2017049011A1 (hr) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4001409A1 (en) | 2006-03-31 | 2022-05-25 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| JP4954326B2 (ja) | 2008-04-11 | 2012-06-13 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
| SG190727A1 (en) | 2010-11-30 | 2013-07-31 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| EP2889376A4 (en) | 2012-08-24 | 2016-11-02 | Chugai Pharmaceutical Co Ltd | ANTIBODIES Fc SPECIFIC TO FCTRII OF MOUSE |
| SG11201500873XA (en) | 2012-08-24 | 2015-04-29 | Chugai Pharmaceutical Co Ltd | Fcgriib-specific fc region variant |
| CN113621057A (zh) | 2013-04-02 | 2021-11-09 | 中外制药株式会社 | Fc区变体 |
| WO2016073853A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| AR103161A1 (es) | 2014-12-19 | 2017-04-19 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso |
| EA201791754A1 (ru) | 2015-02-05 | 2019-01-31 | Чугаи Сейяку Кабусики Кайся | АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ |
| IL258121B2 (en) * | 2015-09-15 | 2024-01-01 | Scholar Rock Inc | Antipro/latent myostatin antibodies and their uses |
| EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE |
| KR20180094110A (ko) | 2016-01-08 | 2018-08-22 | 스칼러 락, 인크. | 항-프로/잠재성 미오스타틴 항체 및 그의 사용 방법 |
| SI3368069T1 (sl) | 2016-06-13 | 2021-03-31 | Scholar Rock, Inc. | Uporaba zaviralcev miostatina in kombinirane terapije |
| CA3026050A1 (en) | 2016-08-05 | 2018-02-08 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of il-8 related diseases |
| WO2018129395A1 (en) * | 2017-01-06 | 2018-07-12 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
| ES2944357T3 (es) * | 2017-01-06 | 2023-06-20 | Scholar Rock Inc | Tratamiento de enfermedades metabólicas inhibiendo la activación de miostatina |
| RS62914B1 (sr) | 2018-07-11 | 2022-03-31 | Scholar Rock Inc | Izoform selektivni inhibitori tgfbeta1 i njihova upotreba |
| JP7540994B2 (ja) | 2018-07-11 | 2024-08-27 | スカラー ロック インコーポレイテッド | 高親和性のアイソフォーム選択的ＴＧＦβ１阻害剤、およびその使用 |
| CN113677711B (zh) | 2019-01-30 | 2025-05-30 | 供石公司 | TGFβ的LTBP复合特异性抑制剂及其用途 |
| CN110429214B (zh) | 2019-08-07 | 2021-12-07 | 宁德时代新能源科技股份有限公司 | 二次电池的盖组件及二次电池 |
| WO2021039945A1 (en) * | 2019-08-28 | 2021-03-04 | Chugai Seiyaku Kabushiki Kaisha | Cross-species anti-latent tgf-beta 1 antibodies and methods of use |
| US20230050148A1 (en) | 2020-01-11 | 2023-02-16 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| RU2750267C1 (ru) * | 2020-02-07 | 2021-06-25 | Общество с ограниченной ответственностью «НАУЧНО-ПРОИЗВОДСТВЕННОЕ ОБЪЕДИНЕНИЕ ИН-ВЕТ» | Рекомбинантный ростовой дифференцировочный фактор роста 11 (GDF11), способ его получения, инъекционный препарат для повышения мышечной массы млекопитающих животных и птицы, а также способ использования препарата |
| CN116390756A (zh) | 2020-10-26 | 2023-07-04 | 供石公司 | 抗前肌生成抑制蛋白/潜伏性肌生成抑制蛋白抗体用于治疗脊髓性肌萎缩的用途 |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| AU2022299185A1 (en) | 2021-06-23 | 2024-01-25 | Scholar Rock, Inc. | A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders |
| CN119451696A (zh) | 2022-05-04 | 2025-02-14 | 供石公司 | 肌生成抑制蛋白抑制剂用于治疗脊髓性肌肉萎缩的用途 |
| AU2023358525A1 (en) | 2022-10-14 | 2025-04-10 | F. Hoffmann-La Roche Ag | Methods for treating spinal muscular atrophy |
| AU2023413166A1 (en) | 2022-12-22 | 2025-07-03 | Scholar Rock, Inc. | Selective and potent inhibitory antibodies of myostatin activation |
| WO2024187051A1 (en) | 2023-03-07 | 2024-09-12 | Scholar Rock, Inc. | Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients |
Family Cites Families (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
| EP0454781B1 (en) | 1989-01-23 | 1998-12-16 | Chiron Corporation | Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| ATE277193T1 (de) | 1989-03-21 | 2004-10-15 | Vical Inc | Expression von exogenen polynukleotidsequenzen in wirbeltieren |
| EP0487587A1 (en) | 1989-08-18 | 1992-06-03 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE185601T1 (de) | 1990-07-10 | 1999-10-15 | Cambridge Antibody Tech | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| AU1545692A (en) | 1991-03-01 | 1992-10-06 | Protein Engineering Corporation | Process for the development of binding mini-proteins |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| JP3534749B2 (ja) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | アデノウイルスが介在する胃腸管への遺伝子の輸送 |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| WO1993025234A1 (en) | 1992-06-08 | 1993-12-23 | The Regents Of The University Of California | Methods and compositions for targeting specific tissue |
| WO1993025698A1 (en) | 1992-06-10 | 1993-12-23 | The United States Government As Represented By The | Vector particles resistant to inactivation by human serum |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| JPH08503855A (ja) | 1992-12-03 | 1996-04-30 | ジェンザイム・コーポレイション | 嚢胞性線維症に対する遺伝子治療 |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US7566768B1 (en) * | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| WO1994021681A1 (en) | 1993-03-19 | 1994-09-29 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| JP3545403B2 (ja) | 1993-04-22 | 2004-07-21 | スカイファルマ インコーポレイテッド | 医薬化合物を被包しているシクロデキストリンリポソーム及びその使用法 |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| DE69435233D1 (de) | 1993-09-15 | 2009-10-08 | Novartis Vaccines & Diagnostic | Rekombinante Alphavirus Vektoren |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| ES2328585T3 (es) | 1993-10-25 | 2009-11-16 | Canji, Inc. | Vector de adenovirus recombinante y metodo de utilizacion. |
| RO116341B1 (ro) | 1993-11-16 | 2001-01-30 | Depotech Corp La Jolia | Lipozom multivezicular si procedeu de obtinere a acestuia |
| ES2297831T3 (es) | 1994-05-09 | 2008-05-01 | Oxford Biomedica (Uk) Limited | Vectores retroviricos que presentan una tasa de recombinacion reducida. |
| US20030167492A1 (en) | 1994-07-08 | 2003-09-04 | Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same |
| EP0776337B1 (en) | 1994-07-08 | 2005-09-21 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-11 |
| AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| AU2998597A (en) | 1996-05-06 | 1997-11-26 | Chiron Corporation | Crossless retroviral vectors |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| CA2364484A1 (en) | 1999-03-09 | 2000-09-14 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
| AU2831801A (en) | 2000-01-28 | 2001-08-07 | Novo Nordisk A/S | Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity |
| EP2281842A1 (en) | 2000-06-16 | 2011-02-09 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to BLyS |
| AU2011244851A1 (en) | 2000-07-27 | 2011-11-24 | The John Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7320789B2 (en) * | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US8455627B2 (en) | 2001-10-05 | 2013-06-04 | Affimed Therapeutics, Ag | Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa |
| EP1300419B1 (en) | 2001-10-05 | 2007-06-13 | Affimed Therapeutics AG | Antibody of human origin for inhibiting thrombocyte aggregation |
| NZ563452A (en) | 2002-07-19 | 2010-04-30 | Abbott Biotech Ltd | Treatment of TNFalpha related disorders |
| DE60331778D1 (de) | 2002-09-16 | 2010-04-29 | Univ Johns Hopkins | Metalloproteaseaktivierung von myostatin und verfahren zur modulation der myostatinaktivität |
| US7261893B2 (en) * | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| WO2004050683A2 (en) | 2002-12-02 | 2004-06-17 | Abgenix, Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
| WO2005066204A2 (en) | 2003-12-31 | 2005-07-21 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
| WO2005084699A1 (en) | 2004-03-02 | 2005-09-15 | Acceleron Pharma Inc. | Alk7 and myostatin inhibitors and uses thereof |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| EP1755648A2 (en) | 2004-05-27 | 2007-02-28 | Acceleron Pharma Inc. | Cerberus/coco derivatives and uses thereof |
| CA2575791A1 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| AU2006208286A1 (en) | 2005-01-26 | 2006-08-03 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| US20060216279A1 (en) | 2005-03-22 | 2006-09-28 | Glass David J | Myostatin inhibiting fusion polypeptides and therapeutic methods thereof |
| EP2295466A3 (en) * | 2005-04-25 | 2011-08-17 | Pfizer Inc. | Antibodies to myostatin |
| US7888486B2 (en) * | 2005-08-19 | 2011-02-15 | Wyeth Llc | Antagonist antibodies against GDF-8 |
| ES2533464T3 (es) | 2005-10-06 | 2015-04-10 | Eli Lilly And Company | Anticuerpos anti-miostatina |
| UA92504C2 (en) * | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| US8067562B2 (en) * | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| WO2007061995A2 (en) | 2005-11-21 | 2007-05-31 | Novartis Ag | Biomarkers for statin-induced myopathy or rhabdomyolysis |
| US8097596B2 (en) | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
| EP2679237A1 (en) | 2006-11-29 | 2014-01-01 | Nationwide Children's Hospital | Myostatin inhibition for enhancing muscle and/or improving muscle function |
| ATE542876T1 (de) | 2007-03-30 | 2012-02-15 | Merck Patent Gmbh | Doppelbrechungsschicht mit negativer optischer dispersion |
| CA2688563A1 (en) | 2007-06-01 | 2008-12-11 | Biogen Idec Ma Inc. | Cripto binding molecules |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| UY32341A (es) | 2008-12-19 | 2010-07-30 | Glaxo Group Ltd | Proteínas de unión antígeno novedosas |
| EP2401293B1 (en) | 2009-02-24 | 2016-02-10 | The Salk Institute For Biological Studies | Designer ligands of tgf-beta superfamily |
| AR076402A1 (es) | 2009-04-27 | 2011-06-08 | Novartis Ag | Composiciones y metodos para aumentar el crecimiento muscular |
| US8178488B2 (en) | 2009-06-08 | 2012-05-15 | Acceleron Pharma, Inc. | Methods for increasing thermogenic adipocytes |
| SG10201501767VA (en) | 2010-03-10 | 2015-05-28 | Genmab As | Monoclonal antibodies against c-met |
| TWI667346B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| TW201210612A (en) * | 2010-06-03 | 2012-03-16 | Glaxo Group Ltd | Humanised antigen binding proteins |
| PH12013500315A1 (en) * | 2010-08-16 | 2013-04-29 | Amgen Inc | Antibodies that bind myostatin, compositions and methods |
| US8551892B2 (en) | 2011-07-27 | 2013-10-08 | Asm Japan K.K. | Method for reducing dielectric constant of film using direct plasma of hydrogen |
| EP2776042B1 (en) | 2011-11-11 | 2019-03-20 | Duke University | Combination drug therapy for the treatment of solid tumors |
| US20130178454A1 (en) | 2011-11-17 | 2013-07-11 | Shalender Bhasin | Combination of testosterone and ornithine decarboxylase (odc) inhibitors |
| WO2013148284A1 (en) | 2012-03-29 | 2013-10-03 | Genentech, Inc. | Antibodies that bind to a pcsk9 cleavage site and methods of use |
| WO2013165972A2 (en) | 2012-04-30 | 2013-11-07 | Cell Signaling Technology, Inc. | Anti-hepatitis b virus antibodies and use thereof |
| CA2876397C (en) | 2012-06-15 | 2019-08-06 | Pfizer Inc. | Improved antagonist antibodies against gdf-8 and uses therefor |
| EP2916867A4 (en) * | 2012-11-06 | 2016-10-05 | Scholar Rock Inc | COMPOSITIONS AND METHOD FOR MODULATING CELL SIGNALING |
| PT2981822T (pt) * | 2013-05-06 | 2020-12-07 | Scholar Rock Inc | Composições e métodos para modulação do fator de crescimento |
| EP2853898B1 (en) | 2013-09-27 | 2017-01-04 | Medizinische Hochschule Hannover | Analysis of myostatin in serum |
| EP3068407A1 (en) | 2013-11-11 | 2016-09-21 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety |
| WO2015195094A1 (en) | 2014-06-17 | 2015-12-23 | Ember Therapeutics, Inc. | Anti-activin and nati-myostatin antibodies and methods of using the same |
| WO2016073906A2 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related immunoassays |
| WO2016073853A1 (en) * | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| AR103161A1 (es) | 2014-12-19 | 2017-04-19 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso |
| CA2982810A1 (en) | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| IL258121B2 (en) | 2015-09-15 | 2024-01-01 | Scholar Rock Inc | Antipro/latent myostatin antibodies and their uses |
| KR20180094110A (ko) | 2016-01-08 | 2018-08-22 | 스칼러 락, 인크. | 항-프로/잠재성 미오스타틴 항체 및 그의 사용 방법 |
| SI3368069T1 (sl) | 2016-06-13 | 2021-03-31 | Scholar Rock, Inc. | Uporaba zaviralcev miostatina in kombinirane terapije |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| ES2944357T3 (es) | 2017-01-06 | 2023-06-20 | Scholar Rock Inc | Tratamiento de enfermedades metabólicas inhibiendo la activación de miostatina |
-
2016
- 2016-09-15 IL IL258121A patent/IL258121B2/en unknown
- 2016-09-15 LT LTEP21170667.6T patent/LT3922645T/lt unknown
- 2016-09-15 ES ES21170667T patent/ES3030258T3/es active Active
- 2016-09-15 CN CN202111206951.0A patent/CN113912718B/zh active Active
- 2016-09-15 CN CN202111206864.5A patent/CN113896790A/zh active Pending
- 2016-09-15 PL PL16774748T patent/PL3350220T3/pl unknown
- 2016-09-15 FI FIEP21170667.6T patent/FI3922645T3/fi active
- 2016-09-15 PT PT211706676T patent/PT3922645T/pt unknown
- 2016-09-15 SM SM20210432T patent/SMT202100432T1/it unknown
- 2016-09-15 EP EP16774748.4A patent/EP3350220B1/en active Active
- 2016-09-15 EP EP21170667.6A patent/EP3922645B1/en active Active
- 2016-09-15 IL IL305148A patent/IL305148A/en unknown
- 2016-09-15 KR KR1020257005821A patent/KR20250033313A/ko active Pending
- 2016-09-15 RS RS20210987A patent/RS62330B1/sr unknown
- 2016-09-15 HU HUE16774748A patent/HUE055331T2/hu unknown
- 2016-09-15 CA CA3036652A patent/CA3036652A1/en active Pending
- 2016-09-15 PT PT167747484T patent/PT3350220T/pt unknown
- 2016-09-15 CN CN201680065184.7A patent/CN108350067B/zh active Active
- 2016-09-15 HR HRP20211081TT patent/HRP20211081T1/hr unknown
- 2016-09-15 ES ES16774748T patent/ES2881642T3/es active Active
- 2016-09-15 WO PCT/US2016/052014 patent/WO2017049011A1/en not_active Application Discontinuation
- 2016-09-15 EP EP24201758.0A patent/EP4461312A3/en active Pending
- 2016-09-15 CN CN202111206744.5A patent/CN113896789A/zh active Pending
- 2016-09-15 SI SI201631287T patent/SI3350220T1/sl unknown
- 2016-09-15 MX MX2018003196A patent/MX2018003196A/es unknown
- 2016-09-15 JP JP2018513591A patent/JP7107836B2/ja active Active
- 2016-09-15 BR BR112018004981-6A patent/BR112018004981A2/pt active Search and Examination
- 2016-09-15 AU AU2016323447A patent/AU2016323447B2/en active Active
- 2016-09-15 KR KR1020237037152A patent/KR102773636B1/ko active Active
- 2016-09-15 DK DK16774748.4T patent/DK3350220T3/da active
- 2016-09-15 US US15/760,393 patent/US10751413B2/en active Active
- 2016-09-15 KR KR1020187010090A patent/KR102596852B1/ko active Active
- 2016-09-15 EA EA201890712A patent/EA038146B1/ru unknown
- 2016-09-15 LT LTEP16774748.4T patent/LT3350220T/lt unknown
- 2016-09-15 DK DK21170667.6T patent/DK3922645T3/da active
-
2018
- 2018-03-14 CO CONC2018/0002703A patent/CO2018002703A2/es unknown
- 2018-03-14 MX MX2022005202A patent/MX2022005202A/es unknown
- 2018-03-14 MX MX2022005211A patent/MX2022005211A/es unknown
- 2018-03-14 MX MX2022005173A patent/MX2022005173A/es unknown
- 2018-03-14 MX MX2022005177A patent/MX2022005177A/es unknown
-
2020
- 2020-06-24 US US16/946,483 patent/US11439704B2/en active Active
-
2021
- 2021-08-10 CY CY20211100716T patent/CY1124619T1/el unknown
-
2022
- 2022-07-12 JP JP2022111605A patent/JP7418508B2/ja active Active
- 2022-07-21 US US17/814,221 patent/US20230190929A1/en active Pending
-
2023
- 2023-06-21 AU AU2023203922A patent/AU2023203922A1/en active Pending
-
2024
- 2024-01-05 JP JP2024000878A patent/JP2024038278A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211081T1 (hr) | Anti-pro/latentna miostatinska protutijela i njihove uporabe | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
| JP2017184723A5 (hr) | ||
| PE20191208A1 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
| HRP20201756T1 (hr) | Antitijela koja sadrže modificirane regije teškog lanca | |
| HRP20191704T1 (hr) | Multispecifična protutijela | |
| PE20240096A1 (es) | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador | |
| PE20241061A1 (es) | Polinucleotidos que codifican receptores de antigeno quimericos de flt3 | |
| RS53042B (en) | ANTIBODIES AGAINST ERBB3 AND THEIR USES | |
| PE20221909A1 (es) | Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf | |
| JP2014221758A5 (hr) | ||
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| PE20211272A1 (es) | POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO | |
| HRP20220811T1 (hr) | Agonistička sredstva za vezanje tnf receptora | |
| HRP20151215T1 (hr) | Anti-nr10 protutijela i njihova uporaba | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| IL299072A (en) | Antibodies and methods of use thereof | |
| AR108663A1 (es) | ANTICUERPOS CONTRA a-SINUCLEÍNA Y SUS USOS | |
| PE20241587A1 (es) | Receptores de antigenos quimericos que se dirigen a flt3 | |
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| FI3677591T3 (fi) | Anti-cd38-vasta-aineet ja fuusiot heikennetylle interferonille alfa-2b | |
| PE20090689A1 (es) | Anticuerpos del antagonista ox40 y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes | |
| PE20140218A1 (es) | Composicion farmaceutica | |
| PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer |